Search Results

Site Search

Frequently asked questions - Insights

For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry...

Mood disorders - Insights

Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.

Oncology - Insights

Offering more than 150 oncology-specific tests in nine subspecialty areas, Mayo Clinic Laboratories’ cancer tests are developed by an experienced team of board-certified geneticists, genetic counselors, and physicians.

Krabbe disease added to federal newborn screening panel - Insights

Thanks to advocacy work by a group of medical experts, including some from Mayo Clinic, the U.S. Department of Health and Human Services now recommends all states screen for infantile Krabbe disease to help save newborn lives.

New tests launched in March - Insights

In March 2023, Mayo Clinic Laboratories announced twenty nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Next-generation sequencing: Examining an often oversimplified & misunderstood technology - Part III - Insights

With the rise of next generation sequencing (NGS) technology, multigene panel testing is expanding so rapidly that clinical practice is racing to keep pace. And questions within genetic tests have expanded along with it, making definitive...

New tests launched in June - Insights

In June 2022, Mayo Clinic Laboratories announced forty-nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Therapeutics - Insights

Developed through evidence-driven clinical innovation and designed to deliver clarity on drug and alcohol use, our testing delivers results that advance understanding and improve outcomes.

Focused lung panel informs the use of targeted cancer therapies - Insights

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

Mayo Clinic Classical Hematology Conference - Insights

This conference will provide reviews and updates about the laboratory and clinical aspects of nonmalignant hematology and bleeding and thrombotic disorders. Combining the clinical and laboratory experience of Mayo Clinic faculty, we will...